XML 36 R17.htm IDEA: XBRL DOCUMENT
v3.20.4

Share-based Compensation | 9 Months Ended
--- | ---
Dec. 31, 2020
Share Based Compensation [Abstract] |
Share-based Compensation | 10. Share-based Compensation We may grant incentive stock options, non-qualified stock options, SSARs, restricted shares, and performance shares under our shareholder-approved 2020 Equity Incentive Plan ("2020 Plan") for up to 2.25 million common shares, plus 868,864 common shares, the number of shares that were remaining for grant under the 2016 Stock Incentive Plan ("2016 Plan") as of the effective date of the 2020 Plan, plus the number of shares remaining for grant under the 2016 Plan that are forfeited, settled in cash, canceled or expired. The aggregate number of shares that may be granted under the 2020 Plan is 3,118,864. We may distribute authorized but unissued shares or treasury shares to satisfy share option and SSAR exercises or restricted share and performance share grants. The fair value of restricted share and performance share grants is based on the closing price of our common shares on the grant date. For stock option and SSAR grants subject to a service condition, we estimate the fair value on the grant date using the Black-Scholes-Merton option pricing model with inputs including the closing market price at grant date, exercise price and assumptions regarding the risk-free interest rate, expected volatility of our common shares based on historical volatility, and expected term as estimated using the simplified method. We record compensation expense for restricted shares and SSAR grants subject to a service condition utilizing the graded vesting method. For SSAR grants subject to a market condition, we estimate the fair value on the grant date through a lattice option pricing model that utilizes a Monte Carlo analysis with inputs including the closing market price at grant date, exercise price, share price threshold, remaining contractual term and assumptions regarding the risk-free interest rate, suboptimal exercise factor, and expected volatility of our common shares based on historical volatility. We record compensation expense for SSAR grants subject to a market condition over the derived service period, which is an output of the lattice option pricing model. The grant date is defined as the date all necessary approvals are obtained. All grants during the nine months ended December 31, 2020 were made under the 2020 Plan, which was approved by our shareholders on November 19, 2020. The Compensation Committee of our Board of Directors approved substantially all grants under the 2020 Plan for the nine months ended December 31, 2020 on June 2, 2020. The closing market price of our common stock was $39.65 and $20.02 on November 19, 2020 and June 2, 2020, respectively. The following table summarizes the share-based compensation expense for SSARs, restricted and performance grants included in the condensed consolidated statements of operations:
|  | Three Months Ended December 31, |  |  | Nine Months Ended December 31, |
(In thousands) |  | 2020 |  |  | 2019 |  |  | 2020 |  |  | 2019 |
Product development |  | $ | 3,362 |  |  | $ | 639 |  |  | $ | 3,773 |  |  | $ | 1,579 |
Sales and marketing |  |  | 666 |  |  |  | 104 |  |  |  | 735 |  |  |  | 217 |
General and administrative |  |  | 2,602 |  |  |  | 586 |  |  |  | 4,804 |  |  |  | 1,360 |
Total share-based compensation expense |  | $ | 6,630 |  |  | $ | 1,329 |  |  | $ | 9,312 |  |  | $ | 3,156 |
Stock-Settled Appreciation Rights SSARs are rights granted to an employee to receive value equal to the difference between the price of our common shares on the date of exercise and the exercise price. The value is settled in common shares of Agilysys, Inc. The following table summarizes the activity during the nine months ended December 31, 2020 for SSARs awarded under the 2020 and 2016 Plans:
|  | Number of Rights |  |  | Weighted-Average Exercise Price |  |  | Remaining Contractual Term |  |  | Aggregate Intrinsic Value |
|  |  |  |  |  | (per right) |  |  | (in years) |  |  |  |  |
Outstanding at April 1, 2020 |  |  | 1,644,888 |  |  | $ | 21.07 |  |  |  |  |  |  |  |  |
Granted |  |  | 2,234,858 |  |  |  | 20.02 |  |  |  |  |  |  |  |  |
Exercised |  |  | (80,255 | ) |  |  | 11.93 |  |  |  |  |  |  |  |  |
Forfeited |  |  | (68,201 | ) |  |  | 19.79 |  |  |  |  |  |  |  |  |
Expired |  |  | (2,118 | ) |  |  | 14.22 |  |  |  |  |  |  |  |  |
Outstanding at December 31, 2020 |  |  | 3,729,172 |  |  | $ | 20.66 |  |  |  | 5.5 |  |  | $ | 66,069 |
Exercisable at December 31, 2020 |  |  | 995,713 |  |  | $ | 14.73 |  |  |  | 3.5 |  |  | $ | 23,544 |
Vested and expected to vest at December 31, 2020 |  |  | 3,729,172 |  |  | $ | 20.66 |  |  |  | 5.5 |  |  | $ | 66,069 |
As of December 31, 2020, total unrecognized share-based compensation expense related to unvested service condition SSARs was $21.1 million, which is expected to be recognized over a weighted-average vesting period of 2.2 years. As of December 31, 2020, total unrecognized share-based compensation expense related to unvested market condition SSARs was $21.9 million, which is expected to be recognized over a weighted-average vesting period of 1.0 years. If the market condition for any SSARs is met prior to the end of their expected vesting period, all remaining unrecognized compensation expense for those SSARs will be recognized at that time. Restricted Shares We granted shares to certain of our Directors, executives and key employees, the vesting of which is service-based. The following table summarizes the activity during the nine months ended December 31, 2020 for restricted shares awarded under the 2020 and 2016 Plans:
|  | Number of Shares |  |  | Weighted-Average Grant-Date Fair Value |
|  |  |  |  |  | (per share) |
Outstanding at April 1, 2020 |  |  | 178,462 |  |  | $ | 19.89 |
Granted |  |  | 56,527 |  |  |  | 39.63 |
Forfeited |  |  | (30,980 | ) |  |  | 20.65 |
Outstanding at December 31, 2020 |  |  | 204,009 |  |  | $ | 25.24 |
The weighted-average grant date fair value of the restricted shares is determined based upon the closing price of our common shares on the grant date. As of December 31, 2020, total unrecognized share-based compensation expense related to unvested restricted stock was $2.4 million, which is expected to be recognized over a weighted-average vesting period of 1.3 years. Performance Shares We awarded certain restricted shares to our Chief Executive Officer, the vesting of which is performance based. The number of shares that vested were based on relative attainment of a performance metric and any unvested shares were forfeited upon settlement of the bonus. The following table summarizes the activity during the nine months ended December 31, 2020 for the performance shares awarded under the 2016 Plan:
|  | Number of Shares |
Outstanding at April 1, 2020 |  |  | 30,120 |
Granted |  |  | — |
Vested |  |  | (6,714 | )
Forfeited |  |  | (23,406 | )
Outstanding at December 31, 2020 |  |  | — |

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_ShareBasedCompensationAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration